Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-α + Ribavirin therapy

Romanian Journal of Gastroenterology

Volumn 12, Issue 2, 2003, Pages 91-95

  Radu, Corina ^a   Dejica, Doru ^a   Mircea, Grigorescu ^a   Teodor, Zaharie ^a   Neculoiu, Daniela ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Clinical Institute of Urology   (Romania)

Author keywords

Chronic hepatitis C; Intercellular adhesion molecule 1 (sICAM 1); Vascular adhesion molecule 1 (sVCAM 1)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; RIBAVIRIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL; MALE; NONHUMAN; VIREMIA; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0037668274     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 2277-2284.
2. Capra F, De Maria E, Lunardi C et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for response to interferon treatment. J Infect Dis 2000; 181: 425-431.
3. Cristea V: Viral hepatitis. In: Clinical immunology textbook. Vol II. D Dejica (cd). Cluj Napoca: Dacia Publ 1998: 73-88.
4. V Cristea. The phases of the immune response and the cooperation between the involve cells. In: Fundamental Immunology. V Cristea (cd). Cluj Napoca: "luliu Hatieganu" University Publ 1999: 208-249.
5. Rehermann B. Immunopathogenesis of hepatitis C. In: Hepatitis CTJ Liang, JH Hoofnagle (eds). New York: Academic Press 2000: 147-168.
6. Rchermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000; 20: 127-141.
7. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001; 79: 515-536.
8. Rosenberg W. Mechanism of immune escape in viral hepatitis. Gut 1999; 44: 759-764.
9. Fukuda Y, Nakano I, Katano Y, Marui A, Hayakawa T. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus. J Int Med Res 1998; 26: 313-318.
10. Lo Iacono O, Garcia Monzon C, Almasio P, Garcia-Bucy L, Craxi A, Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther 1998; 12: 1091-1099.
11. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
12. McHutchison JG, Gordon SC, Schiff ER et al. Interferon α 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
13. Davis GL. Current therapy for chronic hepatitis C. Gastroenterology 2000; 118: S104-S114.
14. Flamm S, Chopra S. Ribavirin in treatment of hepatitis C virus infection. UpToDate, www.uptodate.com 2002: 10.2.
15. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001; 8: 1-18.
16. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000; 7: 250-257.
17. Thomas HC, Torok ME, Forton DM et al. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31: 152-159.
18. Squadrito G, Leone F, Sartori M, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113: 567-572.
19. Zcuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999; 31: 61-64.
20. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
21. Dejica D, Grigoreseu M, Dejica V, et al. Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-α + ribavirin therapy. Rom J Gastroenterol 2002; 11: 277-283.
22. Tortorella C, Sacco R, Orlando P, Salerno MT, Schiaraldi O, Antonaci S. sICAM-1, sCD95 and sCD95L levels in chronic liver disease of different etiology. Immunopharmacol Immunotoxicol 2000; 22: 19-33.
23. Yang SS, Tsai G, Wu CH, Chen DS. Circulating soluble intereellular adhesion molecule-1 in type C viral hepatitis. Hepatogastroenterology 1996; 43: 575-581.
24. Bagnasco M, Riccio AM, Sinelli N et al. Serum intercellular adhesion molecule-1 and long-term response to IFN-α 2b therapy in chronic hepatitis C. J Interferon Cytokine Res 1998; 18: 963-966.